

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/04, A61K 31/435		(11) International Publication Number: WO 99/55706
A1		(43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/SE99/00663 (22) International Filing Date: 23 April 1999 (23.04.99) (30) Priority Data: 9801526-6 29 April 1998 (29.04.98) SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): AMIN, Kosrat [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). DAHLSTRÖM, Michael [FI/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). NORDBERG, Peter [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). STARKE, Ingemar [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). (74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>

(54) Title: IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION

(57) Abstract

The present invention relates to imidazo pyridine derivatives of formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION

TECHNICAL FIELD

5 The present invention relates to novel compounds, and therapeutically acceptable salts thereof, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions
10 containing at least one compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for in the preparation of the novel compounds.

15 BACKGROUND ART

Substituted imidazo[1,2-a]pyridines, useful in the treatment of peptic ulcer diseases, are known in the art, e.g. from EP-B-0033094 and US 4,450,164 (Schering Corporation); from EP-B-0204285 and US 4,725,601 (Fujisawa Pharmaceutical Co.); and from publications by
20 J. J. Kaminski et al. in the Journal of Medical Chemistry (vol. 28, 876-892, 1985; vol. 30, 2031-2046, 1987; vol. 30, 2047-2051, 1987; vol. 32, 1686-1700, 1989; and vol. 34, 533-541, 1991).


For a review of the pharmacology of the gastric acid pump (the H^+ , K^+ -ATPase), see Sachs
25 et al. (1995) Annu. Rev. Pharmacol. Toxicol. 35: 277-305.

DISCLOSURE OF THE INVENTION

It has surprisingly been found that compounds of the Formula I, which are imidazo
30 pyridine derivatives in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position are particularly

effective as inhibitors of the gastrointestinal H^+ , K^+ -ATPase and thereby as inhibitors of gastric acid secretion.

In one aspect, the invention thus relates to compounds of the general Formula I



I

or a pharmaceutically acceptable salt thereof, wherein

10 R^1 is

- (a) H,
- (b) CH_3 , or
- (c) CH_2OH ;

15 R^2 is

- (a) CH_3
- (b) CH_2CH_3

R^3 is

- 20 (a) H
- (b) C_1 - C_6 alkyl,
- (c) hydroxylated C_1 - C_6 alkyl
- (d) halogen

25 R^4 is

- (a) H,
- (b) C₁-C₆ alkyl,
- (c) hydroxylated C₁-C₆ alkyl, or
- (d) halogen;

5

R⁵ is

- (a) H, or
- (b) halogen;

10

R⁶, R⁷ are the same or different

- (a) H,
- (b) C₁-C₆ alkyl;
- (c) hydroxylated C₁-C₆ alkyl
- (d) C₁-C₆ alkoxy-substituted C₁-C₆ alkyl

15

X is

- (a) NH, or
- (b) O.

20

As used herein, the term "C₁-C₆ alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said C₁-C₆ alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and
25 hexyl.

The term "halogen" includes fluoro, chloro, bromo and iodo.

Both the pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers are
30 within the scope of the invention. It should be understood that all the diastereomeric forms possible (pure enantiomers, racemic mixtures and unequal mixtures of two enantiomers) are within the scope of the invention. Also included in the invention are derivatives of the compounds of the Formula I which have the biological function of the compounds of the Formula I, such as prodrugs.

It will also be appreciated by those skilled in the art, although derivatives of compounds of formula I may not possess pharmacological activity as such, they may be administered parenterally or orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of formula I are included within the scope of the invention.

Depending on the process conditions the end products of the Formula I are obtained either in neutral or salt form. Both the free base and the salts of these end products are within the scope of the invention.

Acid addition salts of the new compounds may in a manner known *per se* be transformed into the free base using basic agents such as alkali or by ion exchange. The free base obtained may also form salts with organic or inorganic acids.

In the preparation of acid addition salts, preferably such acids are used which form suitably therapeutically acceptable salts. Examples of such acids are hydrohalogen acids such as hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxyl or sulphonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulphonic acid, ethanesulphonic acid, hydroxyethanesulphonic acid, halogenbenzenesulphonic acid, toluenesulphonic acid or naphthalenesulphonic acid.

Preferred compounds according to the invention are those of the Formula I wherein R^1 is CH_3 or CH_2OH ; R^2 is CH_3 or CH_2CH_3 ; R^3 is CH_3 or CH_2CH_3 ; R^4 is CH_3 or CH_2CH_3 ; R^5 is H, Br, Cl, or F.

Particularly preferred compounds according to the invention are:

- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-propyl-imidazo[1,2-a]pyridine-6-carboxamide
- 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide
- 5 • 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide
- 8-(2-ethyl-6-methylbenzylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-
- 10 carboxamide
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate
- 2,3-dimethyl-8-(2-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 15 • 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate
- 2,3-dimethyl-8-(2-methyl-6-isopropylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate
- 2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 20 • 2,3-dimethyl-8-(2-ethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide
- N-(2,3-dihydroxypropyl)-2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-[1,2-a]pyridine-6-carboxamide
- 25 • 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide
- 2-methyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2-bromo-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2-(2-hydroxyethyl)-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-
- 30 carboxamide
- 8-(2-ethyl-6-methylbenzylamino)-N,N-bis(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
- 8-(2-ethyl-6-methylbenzylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide

- 2,3-dimethyl-8-(2-ethyl-6-methylbenzyloxy)-imidazo[1,2-a]pyridine-6-carboxamide

Most preferred compounds according to the invention are:

- 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide
- 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide

Preparation


The present invention also provides the following processes A, B and C for the manufacture of compounds with the general Formula I.

Process A

Process A for manufacture of compounds with the general Formula I wherein X is NH comprises the following steps:

- a) Compounds of the general Formula II


7



II

can be reacted with amino compounds of the general Formula III


5



III

wherein R⁶ and R⁷ are as defined for Formula I, to the corresponding amide of the Formula IV. The reaction can be carried out in standard conditions in an inert solvent.


10



IV

b) Compounds of the general Formula IV can be reacted with ammonia to compounds of the general Formula V


15



wherein R^6 and R^7 are as defined for Formula I. The reactions can be carried out under standard conditions in an inert solvent.

5

c) Compounds of the Formula V can be reduced e.g. by using hydrogen and a catalyst such as Pd/C to compounds of the Formula VI




10

wherein R^6 and R^7 are as defined for Formula I. The reaction can be carried out under standard conditions in an inert solvent.

d) The imidazo[1,2-a]pyridine compounds of the Formula VIII can be prepared by reacting compounds of the general Formula VI with compounds of the general Formula VII


15




wherein R^2 is as defined for Formula I and Z is a leaving group such as halogen, mesyl, tosyl and R^9 represents H, CH_3 or an ester group such as $COOCH_3$, $COOC_2H_5$ etc.

20


The reaction is carried out under standard conditions in an inert solvent such as acetone, acetonitrile, alcohol, dimethylformamide, etc. with or without a base.



e) Compounds of the Formula VIII can be reacted with compounds of the Formula IX



wherein R³, R⁴ and R⁵ are as defined for Formula I and Y is a leaving group, such as a halide, tosyl or mesyl, to the compounds of the Formula X.




wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined for Formula I and R^9 is H, CH_3 or an ester group such as $COOCH_3$, $COOC_2H_5$, etc. It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol or dimethylformamide with or without a base. The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium hydroxide, an alkali metal carbonate, such as potassium carbonate and sodium carbonate; or an organic amine, such as triethylamine.

f) Reduction of compounds of the general Formula X wherein R^9 is an ester group e.g. by using lithium borohydride in an inert solvent such as tetrahydrofuran or diethyl ether, to the compounds of the general Formula I wherein R^1 is CH_2OH .

Process B


Process B for manufacture of compounds with the general Formula I wherein R^1 is H or CH_3 and X is NH comprises the following steps:

a) Compounds of the general Formula II



II


can be reacted with an alcohol compound of the general Formula $R^{10}-OH$, wherein R^{10} is an alkyl group such as methyl, ethyl, etc. to the corresponding ester of Formula XI.



XI

The reactions can be carried out under standard conditions .

- 5 b) Compounds of the general Formula XI can be reacted with ammonia to compounds of the general Formula XII




XII

- 10 wherein R^{10} is an alkyl group such as methyl or ethyl, etc. The reactions can be carried out under standard conditions in an inert solvent.

- c) Compounds of the Formula XII can be reduced e.g. by using hydrogen and a catalyst such as Pd/C to compounds of the Formula XIII


15



XIII


wherein R^{10} is an alkyl group such as methyl, ethyl etc. The reaction can be carried out under standard conditions in an inert solvent.

- d) The imidazo[1,2-a]pyridine compounds of the Formula XV wherein R^{10} is an alkyl group such as methyl, ethyl etc, can be prepared by reacting compounds of the general Formula XIII with compounds of the general Formula XIV




XIV

- wherein R^2 is as defined for Formula I, Z is a leaving group such as halogen, mesyl or tosyl and R^{11} represents H or CH_3 . The reaction is carried out under standard conditions in an inert solvent such as acetone, acetonitrile, alcohol, dimethylformamide etc, with or without a base.




XV

- e) Compounds of the Formula XV can be reacted with compounds of the Formula IX



IX


wherein R^3 , R^4 and R^5 are as defined for Formula I and Y is a leaving group, such as a halide, tosyl or mesyl, to the compounds of the Formula XVI.



XVI

wherein R^2 , R^3 , R^4 and R^5 are as defined for Formula I, R^{10} is an alkyl group such as methyl, ethyl, etc. and R^{11} is H, or CH_3 . It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol or dimethylformamide with or without a base. The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium hydroxide, an alkali metal carbonate, such as potassium carbonate and sodium carbonate; or an organic amine, such as triethylamine.

f) Compounds of the Formula XVI can be reacted with amino compounds of the general Formula III



III


wherein R^6 and R^7 are as defined in Formula I to the corresponding amide of the Formula I wherein R^1 is H or CH_3 and X is NH. The reaction can be carried out by heating the reactants in the neat amino compound or in an inert solvent under standard conditions.

Process C

Process C for manufacture of compounds with the general Formula I comprises the following steps:


5

a) Treating compounds of Formula XVII



XVII

10 wherein R¹, R², R³, R⁴, R⁵, and X are as defined in Formula I and R¹⁰ is an alkyl group such as methyl, ethyl, etc, with acid or base under standard conditions can hydrolyzed them to the corresponding carboxylic acid compounds of Formula XVIII



XVIII

b) Compounds of the Formula XVIII wherein R¹, R², R³, R⁴, R⁵ and X are as defined in Formula I can be reacted with amino compounds of Formula III in the presence of a coupling reagent to the corresponding amide compounds of the Formula I. The reaction can be carried out in an inert solvent under standard conditions.

5

Medical use

In a further aspect, the invention relates to compounds of the formula I for use in therapy, in particular for use against gastrointestinal inflammatory diseases. The invention also provides the use of a compound of the formula I in the manufacture of a medicament for the inhibition of gastric acid secretion, or for the treatment of gastrointestinal inflammatory diseases.

The compounds according to the invention may thus be used for prevention and treatment of gastrointestinal inflammatory diseases, and gastric acid-related diseases in mammals including man, such as gastritis, gastric ulcer, duodenal ulcer, reflux esophagitis and Zollinger-Ellison syndrome. Furthermore, the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable, e.g. in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre-and postoperatively to prevent acid aspiration and stress ulceration.

The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 1000 mg per day of active substance.

25

Pharmaceutical formulations

In yet a further aspect, the invention relates to pharmaceutical compositions containing at least one compound of the invention, or a therapeutically acceptable salt thereof, as active
5 ingredient.

The compounds of the invention can also be used in formulations together with other active ingredients, e.g. antibiotics such as amoxicillin.

10 For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. The pharmaceutical formulation contains at least one compound of the invention in combination with one or more pharmaceutically acceptable ingredients. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical
15 preparations are a further object of the invention. Usually the amount of active compounds is between 0.1–95% by weight of the preparation, preferably between 0.1–20% by weight in preparations for parenteral use and preferably between 0.1 and 50% by weight in preparations for oral administration.

20 In the preparation of pharmaceutical formulations containing a compound of the present invention in the form of dosage units for oral administration the compound selected may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium
25 stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or pressed into tablets.

Soft gelatin capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for
30 soft gelatin capsules. Hard gelatin capsules may contain granules of the active compound. Hard gelatin capsules may also contain the active compound in combination with solid

powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.

5 Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

10 Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.1% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid
15 preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

20 Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent, preferably in a concentration from 0.1% to 10% by weight. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to by
25 reconstituted with a suitable solvent extemporaneously before use.

The compounds according to the present invention can also be used in formulations, together or in combination for simultaneous, separate or sequential use, with other active ingredients, e.g. for the treatment or prophylaxis of conditions involving infection by
30 *Helicobacter pylori* of human gastric mucosa. Such other active ingredients may be antimicrobial agents, in particular:

- β -lactam antibiotics such as amoxicillin, ampicillin, cephalothin, cefaclor or cefixime;
- macrolides such as erythromycin, or clarithromycin;
- tetracyclines such as tetracycline or doxycycline;
- aminoglycosides such as gentamycin, kanamycin or amikacin;
- 5 • quinolones such as norfloxacin, ciprofloxacin or enoxacin;
- others such as metronidazole, nitrofurantoin or chloramphenicol; or
- preparations containing bismuth salts such as bismuth subcitrate, bismuth subsalicylate, bismuth subcarbonate, bismuth subnitrate or bismuth subgallate.


10 The compounds according to the present invention can also be used together or in combination for simultaneous, separate or sequential use with antacids such as aluminium hydroxide, magnesium carbonate and magnesium hydroxid or alginic acid, or together or in combination for simultaneous, separate or sequential use with pharmaceuticals which inhibit acid secretion, such as, H₂-blockers (*e.g.* cimetidine, 15 ranitidine), H⁺/K⁺ - ATPase inhibitors (*e.g.* omeprazole, pantoprazole, lansoprazole or rabeprazole), or together or in combination for simultaneous, separate or sequential use with gastroprokinetics (*e.g.* cisapride or mosapride).

20 *Intermediates*

A further aspect of the invention is new intermediate compounds which are useful in the synthesis of compounds according to the invention.

25 Thus, the invention includes

(a) a compound of the formula VIII




VIII

wherein R^2 , R^6 and R^7 are as defined for Formula I, and R^9 is H, CH_3 or an ester group such as $COOCH_3$, $COOC_2H_5$, etc.;

5


(b) a compound of the formula X



X

10 wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined for Formula I, and R^9 is an ester group such as $COOCH_3$, $COOC_2H_5$ etc.;

(c) a compound of the formula XV




XV

15

wherein R^2 is as defined for Formula I, R^{10} is an alkyl group and R^{11} is H or CH_3 ;


(d) a compound of the formula XVI



XVI

wherein R^2 , R^3 , R^4 and R^5 are as defined for Formula I, R^{10} is an alkyl group and R^{11} is H or CH_3 ;

(e) a compound of the formula XVIII



XVIII

wherein R^1 , R^2 , R^3 , R^4 , R^5 and X are as defined for


Formula I.

EXAMPLES

1. PREPARATION OF COMPOUNDS OF THE INVENTION

Example 1.1

10 *Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-propyl-imidazo[1,2-a]pyridine-6-carboxamide*




15 Ethyl 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate (0.12 g, 0.33 mmol), propylamine (1.0 g, 17 mmol) and a cat. amount of sodium cyanide were refluxed in methanol (20 ml) for 24 h. An additional amount of propylamine (1.0 g, 17 mmol) was added and the reaction mixture was refluxed for 24 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography
20 on silica gel using diethyl ether as eluent. Crystallization from diethyl ether gave 0.053 g (42%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.0 (t, 3H), 1.2 (t, 3H), 1.65-1.75 (m, 2H), 2.3 (s, 3H), 2.35 (s, 3H), 2.38 (s, 3H), 2.7 (q, 2H), 3.4-3.5 (m, 2H), 4.35 (d, 2H), 4.9 (bs, 1H), 6.2 (bs, 1H), 6.35 (s, 1H), 7.0-7.2 (m, 4H), 7.85 (s, 1H).

5. *Example 1.2*

Synthesis of 8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide



10

Ethyl 6-(aminocarbonyl)-8-(2-ethyl-6-methylbenzylamino)-2-methylimidazo[1,2-a]pyridine-3-carboxylate (280 mg, 0.71 mmol) and lithium borohydride (16 mg, 0.71 mmol) were added to tetrahydrofuran (10 ml) and the reaction mixture was refluxed for 70 min. Additional amounts of lithium borohydride (16 mg) and methanol (45 mg, 1.42 mmol) were added and the mixture was refluxed for 80 min. Additional amounts of lithium borohydride (16 mg) and methanol (22 mg, 71 mmol) were added and the mixture was refluxed for 4 h. The reaction mixture was allowed to reach R.T. and water (1 ml) and methanol (5 ml) and was stirred for 40 min. at R.T. The solvents were evaporated under reduced pressure and the residue was added to water and was stirred for 80 min. The crystals were filtered off and washed with water, ethyl acetate/ethanol and diethyl ether to give the desired product (115 mg, 46 %).


15

20

¹H-NMR (300 MHz, DMSO-d₆): δ 1.15 (t, 3H), 2.25 (s, 3H), 2.35 (s, 3H), 2.7 (q, 2H), 4.35 (d, 2H), 4.75 (d, 2H), 4.85 (t, 1H), 5.1 (t, 1H), 6.8 (s, 1H), 7.1-7.25 (m, 3H), 7.4 (bs, 1H), 8.05 (bs, 1H), 8.3 (s, 1H)

5 *Example 1.3*

Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide




10

Methyl 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate (0.12 g, 0.33 mmol), ethanolamine (0.2 g, 3.3 mmol) and sodium cyanide (10 mg, 0.2 mmol) were refluxed in dimethoxyethane (2 ml) for 20 h. The solvent was evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using methylene chloride : methanol (92:8) as eluent gave the product which was washed with diethyl ether to give 103 mg (79%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 2.3 (s, 6H), 2.35 (s, 6H), 3.5-3.6 (m, 2H), 3.75-3.8 (m, 2H), 4.3 (d, 2H), 4.95 (t, 1H), 6.4 (s, 1H), 6.85 (t, 1H), 7.0-7.2 (m, 3H), 7.75 (s, 1H)

20


*Example 1.4**Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide*

8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide (3.3 g, 16.2 mmol), 2-ethyl-6-methylbenzylchloride (2.73 g, 16.2 mmol), potassium carbonate (8.0 g, 58 mmol) and potassium iodide (1.1 g, 6.6 mmol) were added to acetone (150 ml) and refluxed for 20 h. An additional amount of 2-ethyl-6-methylbenzylchloride (1.0 g, 5.9 mmol) was added and the reaction mixture was refluxed for 7 h. Methylene chloride (60 ml) and methanol (30 ml) were added. The reaction mixture was filtered and the solvents were evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride: methanol (100:7) as eluent. Crystallization from ethyl acetate gave 2.8 g (50%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 3H), 2.34 (s, 3H), 2.36 (s, 3H), 2.38 (s, 3H), 2.7 (q, 2H), 4.4 (d, 2H), 4.9 (bs, 1H), 6.0 (bs, 2H), 6.45 (s, 1H), 7.0-7.2 (m, 3H), 7.9, (s, 1H).

*Example 1.5**Synthesis of 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide*

5



2,3-Dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (0.15 g, 0.44 mmol) and o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TBTU) (0.14 g, 0.44 mmol) were added to methylene chloride (10 ml) and the reaction mixture was stirred at room temperature for 15 min. Methylamine (0.1 g, 3.2 mmol) was added and the reaction mixture was stirred at ambient temperature for 1.5 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using ethylacetate : methylene chloride (1:1) as eluent. The yield was treated with diethyl ether to give 40 mg (26 %) of the desired product .


15

¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 3H), 2.33 (s, 3H), 2.36 (s, 3H), 2.38 (s, 3H), 2.7 (q, 2H), 3.05 (d, 3H), 4.35 (d, 2H), 4.9 (t, 1H), 6.3 (bs, 1H), 6.4 (s, 1H), 7.0-7.2 (m, 3H), 7.85 (s, 1H)

20


*Example 1.6**Synthesis of 8-(2-ethyl-6-methylbenzylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide*

5



2,3-Dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (0.15 g, 0.44 mmol) and o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TBTU) (0.14 g, 0.44 mmol) were added to methylene chloride (10 ml). Dimethylamin (0.063 g, 1.4 mmol) was added and the reaction mixture was stirred at ambient temperature for 4 h. An additional amount of dimethylamin (0.1 ml) was added and the mixture was stirred at room temperature for 20 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography using methylene chloride : methanol (9:1) as eluent. The oily product was treated with heptane and the solid that formed was filtered off to give 0.1 g (62 %) of the title compound.


¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 3H), 2.35 (s, 6H), 2.4 (s, 3H), 2.7 (q, 2H), 3.15 (s, 6H), 4.4 (d, 2H), 4.9 (t, 1H), 6.25 (s, 1H), 7.0-7.2 (m, 3H), 7.45 (s, 1H)

*Example 1.7**Synthesis of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide*

8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide (0.6 g, 2.9 mmol), 2,6-dimethylbenzylchloride (0.45 g, 2.9 mmol), sodium carbonate (1.0 g, 9.4 mmol) and potassium iodide (0.2 g, 1.3 mmol) were added to acetone (25 ml) and refluxed for 19 h. Methylene chloride was added and inorganic salts were filtered off. The solution was washed with a bicarbonate solution, the organic layer was separated, dried and the solvents were evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride : methanol (100 : 5) as eluent and the product was washed with diethyl ether to give 0.78 g (82 %) of the title compound.

¹H-NMR (500 MHz, CDCl₃): δ 2.33 (s, 3H), 2.4 (s, 6H), 2.42 (s, 3H), 4.4 (d, 2H), 2.95 (bs, 1H), 6.45 (s, 1H), 7.05-7.15 (m, 3H), 7.95 (s, 1H)

*Example 1.8**Synthesis of 2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate*




8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (0.7 g, 1.9 mmol),
 2-ethyl-4-fluoro-6-methylbenzylchloride (0.26 g, 1.9 mmol) and diisopropylethylamin
 (0.54 g, 4.2 mmol) were added to dimethylformamide (5 ml) and stirred at room
 temperature for 1 h. Methylene chloride and water were added to the reaction mixture, the
 organic layer was separated, dried and evaporated under reduced pressure. The residue was
 solved in ethylacetate and ethanol and metanesulfonic acid (0.2 g, 2 mmol) was added. The
 product was filtered off and was solved in methylene chloride:methanol (2:1) and an excess
 of potassium carbonate. The solids were filtered off and the solvent was evaporated under
 reduced pressure. The residue was purified by column chromatography on silica gel using
 methylene chloride: methanol (10:1) as eluent. The residue was solved in ethylacetate and
 methansulfonic acid (0.04 g, 0.4 mmol) was added. The salt was filtered off to give 0.2 g
 (23 %) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ 1.15 (t, 3H), 2.25 (s, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 2.45
 (s, 3H), 2.6 (q, 2H), 4.35 (d, 2H), 6.15 (bs, 1H), 6.95-7.05 (m, 2H), 7.4 (s, 1H), 7.8 (bs,
 1H), 8.3 (bs, 1H), 8.45 (s, 1H)

Example 1.9

Synthesis of 2,3-dimethyl-8-(2-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide




8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (1.0 g, 2.7 mmol), α -chloro-o-xylene (0.38 g, 2.7 mmol) and diisopropylethylamin (0.76 g, 5.9 mmol) in dimethylformamide (7 ml) were stirred at 50 °C for 7 h and at room temperature for 72 h. The solvent was evaporated and the residue was treated with a mixture of methylene chloride, water and a small amount of diisopropylethylamin. The solid that formed was isolated by filtration and washed with ethylacetate to give 0.11 g (13 %) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ 2.3 (s, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 4.45 (d, 2H), 6.3-6.4 (m, 2H), 7.1-7.25 (m, 4H), 7.3 (bs, 1H), 7.85 (bs, 1H), 8.05 (s, 1H)

Example 1.10

Synthesis of 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate




8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (5.0 g, 13.4 mmol), 2,6-dimethyl-4-fluorobenzylbromide (2.91 g, 13.4 mmol), diisopropylethylamin (3.8 g, 29.5 mmol) and a cat. amount of potassium iodide were stirred in dimethylformamide (20 ml) at room temperature overnight. Water (70 ml) and methylene chloride (2 x 50 ml) were added to the reaction mixture and the organic layer was separated, dried and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride: methanol (9:1) as eluent. The product was solved in isopropanol and methansulfonic acid (0.3 g) was added. The salt that formed was isolated by filtration and washed with isopropanol and diethyl ether to give 1.4 g (24 %) of the title compound.

¹H-NMR (500 MHz, DMSO-d₆): δ 2.25 (s, 3H), 2.35 (s, 6H), 2.4 (s, 3H), 2.5 (s, 3H), 4.4 (d, 2H), 6.1 (bs, 1H), 7.0 (d, 2H), 7.35 (s, 1H), 7.8 (bs, 1H), 8.3 (bs, 1H), 8.45 (s, 1H)

Example 1.11

Synthesis of 2,3-dimethyl-8-(2-methyl-6-isopropylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate



20


8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (3.0 g, 8.0 mmol), 2-methyl-6-isopropylbenzylchloride (1.47 g, 8.0 mmol), diisopropylethylamin (2.4 g, 18.6 mmol) and a cat. amount of potassium iodide in dimethylformamide (15 ml). The title compound were prepared according to Example 1.10 (Yield: 1.3 g, 36 %)

25

¹H-NMR (300 MHz, DMSO-d₆): δ 1.2 (d, 6H), 2.25 (s, 3H), 2.4 (s, 3H), 2.45 (s, 3H), 2.5 (s, 3H), 3.2 (m, 1H), 4.45 (d, 2H), 6.15 (bs, 1H), 7.15-7.3 (m, 3H), 7.4 (s, 1H), 7.85 (bs, 1H), 8.35 (bs, 1H), 8.45 (s, 1H)

5 *Example 1.12*

Synthesis of 2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide



10

8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (4.0 g, 10.7 mmol), 2,6-diethylbenzylchloride (1.8 g, 9.9 mmol), diisopropylethylamin (3.0 g, 23.3 mmol) were stirred in dimethylformamide (20 ml) at 50 °C overnight and at 70 °C for 3 h. Water (60 ml) and methylene chloride were added and the organic layer was separated, dried and evaporated under reduced pressure. The residue was treated with diethyl ether and the product was filtered off to give 1.7 g (45 %) of the title compound.


¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 6H), 2.35 (s, 3H), 2.4 (s, 3H), 2.7 (q, 4H), 4.4 (d, 2H), 4.95 (bs, 1H), 6.15 (bs, 2H), 6.5 (s, 1H), 7.05-7.25 (m, 3H), 7.95 (s, 1H)

20

Example 1.13

Synthesis of 2,3-dimethyl-8-(2-ethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide

25




8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (4.0 g, 10.7 mmol),
2-ethylbenzylchloride (1.65 g, 10.7 mmol), diisopropylethylamin (3.0 g, 23.3 mmol) in
diethylformamide (20 ml).

The title compound was prepared according to Example 1.12 (Yield: 1.15 g, 26 %)

¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 3H), 2.3 (s, 3H), 2.35 (s, 3H), 2.75 (q, 2H), 4.5 (d, 2H), 6.3 (t, 1H), 6.4 (s, 1H), 7.05-7.25 (m, 4H), 7.3 (bs, 1H), 7.85 (bs, 1H), 8.05 (s, 1H)

Example 1.14

Synthesis of 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide




2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid
(0.3 g, 0.88 mmol) and o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium
tetrafluoroborate (TBTU)(0.29 g, 0.90 mmol) were added to methylene chloride (15 ml)

and the mixture was stirred for 5 min. Ethanolamin (0.11g, 1.8 mmol) was added and the reaction mixture was stirred at ambient temperature for 2 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride:methanol (9:1) as eluent. Crystallization from diethyl ether gave 0.2 (59 %) of the desired product.

¹H-NMR (500 MHz, CDCl₃): δ 1.2 (t, 3H), 2.3 (s, 6H), 2.35 (s, 3H), 2.7 (q, 2H), 3.55-3.6 (m, 2H), 3.8-3.85 (m, 2H), 4.35 (d, 2H), 4.9 (t, 1H), 6.4 (s, 1H), 6.85 (t, 1H), 7.05-7.2 (m, 3H), 7.75 (s, 1H)

Example 1.15

Synthesis of N-(2,3-dihydroxypropyl)-2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-[1,2-a]pyridine-6-carboxamide




2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (0.3 g, 0.88 mmol), o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TBTU) (0.29 g, 0.90 mmol) and 3-amino-1,2-propanediol (0.16 g, 1.81 mmol) in dimethylformamide (10 ml).

The title compound was prepared according to Example 1.14 (Yield: 0.2 g, 54 %)

¹H-NMR (500 MHz, CDCl₃): δ 1.2 (t, 3H), 1.82-1.85 (m, 1H), 2.32 (s, 3H), 2.33 (s, 3H), 2.36 (s, 3H), 2.7 (q, 2H), 3.5-3.65 (m, 4H), 3.72-3.77 (m, 1H), 3.85-3.91 (m, 1H), 4.34 (d, 2H), 5.04 (t, 1H), 6.4 (d, 1H), 6.89 (t, 1H), 7.04-7.12 (m, 2H), 7.18 (t, 1H), 7.78 (d, 1H)

Example 1.16

Synthesis of 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide



2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid
(0.15 g, 0.44 mmol), o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium
tetrafluoroborate (TBTU)(0.14 g, 0.44 mmol) and 2-methoxyethylamin (0.11 g, 1.4 mmol)
in methylene chloride (10 ml).


The title compound were prepared according to Example 1.14

Crystallization from hexane:ethylacetate. (Yield: 0.09 g, 53 %)

¹H-NMR (400 MHz, CDCl₃): δ 1.22 (t, 3H), 2.34 (s, 3H), 2.38 (s, 3H), 2.39 (s, 3H), 2.71
(q, 2H), 3.42 (s, 3H), 3.6-3.72 (m, 4H), 4.38 (d, 2H), 4.91 (t, 1H), 6.42 (s, 1H), 6.58 (t, 1H),
7.04-7.2 (m, 3H), 7.88 (s, 1H)

Example 1.17

Synthesis of 2-methyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide




8-Amino-2-methylimidazo[1,2-a]pyridine-6-carboxamide (3.8 g, 20 mmol), 2-ethyl-6-methylbenzylchloride (2.8 g, 17 mmol), potassium carbonate (5.5 g, 40 mmol) and sodium iodide (0.1 g, 0.6 mmol) were added to dimethylformamide (75 ml) and the mixture was stirred at 50 °C for 4 h. and at room temperature for 48 h. The reaction mixture was filtered through silica gel and the gel was washed with methylene chloride. The solvents were evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride: methanol (9:1) as eluent. Crystallization from a mixture of methylene chloride and hexane gave 0.13 g (2 %) of the title compound.

¹H-NMR (400 MHz, CDCl₃): δ 1.15 (t, 3H), 2.31 (s, 6H), 2.64 (q, 2H), 4.32 (d, 2H), 4.89 (bs, 1H), 6.36 (s, 1H), 7.0-7.15 (m, 3H), 7.23 (s, 3H), 8.03 (s, 1H)

Example 1.18

Synthesis of 2,3-dimethyl-8-(2-bromo-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide




8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate (1.0 g, 5.0 mmol),
 2-bromo-6-methylbenzylchloride (45%)(3.0 g, 5.0 mmol) and diisopropylethylamine (2.2 g,
 17 mmol) were added to dimethylformamide (50 ml) and stirred at 50 °C for 48 h.
 Methylene chloride and water were added to the reaction mixture, the organic layer was
 separated, washed with saturated sodium chloride, dried (Na_2SO_4) and evaporated under
 reduced pressure. Purification of the residue twice by column chromatography on silica gel
 using methylene chloride: methanol (10:1) and ethylacetate as eluent gave 0.18 g (1 %) of
 the desired product.

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 2.28 (s, 3H), 2.30 (s, 3H), 2.36 (s, 3H), 4.48 (d, 2H), 5.0
 (bs, 1H), 6.05 (bs, 2H), 6.41 (d, 1H), 6.95-7.1 (m, 2H), 7.37 (d, 1H), 7.87 (d, 1H)

Example 1.19

Synthesis of 2,3-dimethyl-8-(2-(2-hydroxyethyl)-6-methylbenzylamino)-imidazo[1,2-
 a]pyridine-6-carboxamide




2,3-dimethyl-8-(2-(2-(benzyloxy)ethyl)-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide (0.13 g, 0.29 mmol), cyclohexene (1 ml), Pd(OH)₂ cat. (25 mg) were added to ethanol (5 ml) and the mixture was refluxed overnight. An additional amount of
 5 cyclohexene (1 ml) and Pd(OH)₂ cat. (25 mg) were added and the mixture was refluxed for 4 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride: methanol (9:1) as eluent. Treating the residue with chloroform and filtration gave 0.1 g (99 %) of the title compound.

10 ¹H-NMR (400 MHz, CD₃OD): δ 2.29 (s, 3H), 2.40 (s, 3H), 2.42 (s, 3H), 2.94 (t, 2H), 3.74 (t, 2H), 4.47 (s, 2H), 6.83 (d, 1H), 7.11-7.20 (m, 3H), 8.12 (d, 1H)

Example 1.20

15 *Synthesis of 8-(2-ethyl-6-methylbenzylamino)-N,N-bis(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide*




20 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (0.3 g, 0.88 mmol), o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TBTU)(0.3 g, 0.94 mmol) and diethanolamine (0.2 g, 1.9 mmol) in methylene chloride (10 ml).

25 The title compound were prepared according to Example 1.14 (Yield: 0.19 g, 50 %)

¹H-NMR (400 MHz, CDCl₃): δ 1.2 (t, 3H), 2.3 (s, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 2.7 (q, 2H), 3.65 (bs, 4H), 3.9 (bs, 4H), 4.35 (d, 2H), 4.95 (bs, 1H), 6.35 (s, 1H), 7.0-7.2 (m, 3H), 7.7 (s, 1H)

5 *Example 1.21*

Synthesis of 8-(2-ethyl-6-methylbenzylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide



10

2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (0.3 g, 0.88 mmol), o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TBTU) (0.3 g, 0.94 mmol) and 2-(methylamino)ethanol (0.2 g, 2.66 mmol) in methylene chloride (10 ml).

15


The title compound were prepared according to Example 1.14 (Yield: 0.25 g, 71 %)

¹H-NMR (600 MHz, CDCl₃): δ 1.2 (t, 3H), 2.25 (s, 6H), 2.35 (s, 3H), 2.7 (q, 2H), 3.15 (s, 3), 3.65 (bs, 2H), 3.9 (bs, 2H), 4.35 (d, 2H), 5.0 (bs, 1H), 6.25 (bs, 1H), 7.0-7.25 (m., 3H), 7.45 (bs, 1H)

20

Example 1.22

25 *Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzyloxy)-imidazo[1,2-a]pyridine-6-carboxamide*



6-amino-5-(2-ethyl-6-methylbenzyloxy)nicotinamide (0.14 g, 0.49 mmol), 3-bromo-2-butanone (0.075 g, 0.49 mmol) and sodium bicarbonate (0.1 g, 1.2 mmol) was added to acetonitrile (3 ml) and was refluxed for 20 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride: methanol (9:1) as eluent. Crystallization from acetonitrile gave 0.058 g (35 %) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ 1.14 (t, 3H), 2.24 (s, 3H), 2.33 (s, 3H), 2.40 (s, 3H), 2.69 (q, 2H), 5.25 (s, 2H), 7.1-7.3 (m, 4H), 7.51 (bs, 1H), 8.08 (bs, 1H), 8.42 (s, 1H)

2. PREPARATION OF INTERMEDIATES

Example 2.1

Synthesis of methyl 6-amino-5-nitronicotinate

6-Chloro-5-nitronicotinoyl chloride (22.0 g, 0.1 mol) was cooled to +5°C. Methanol was added dropwise during 30 min and the reaction mixture was stirred for 60 min. The temperature was not allowed to raise over +10°C. Ammonium hydroxide (25%, 400 ml) was added dropwise to the reaction mixture and the mixture was stirred at room temperature for 20 h. The product was filtered off, washed with water and dried to give 9.0 g (45.9%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 3.95 (s, 3H), 6.3 (bs, 1H), 8.0 (bs, 1H), 8.95 (s, 1H), 9.05 (s, 1H)

Example 2.2

5

Synthesis of methyl 5,6-diaminonicotinate

Methyl 6-amino-5-nitronicotinate (9.0 g, 46 mmol) and a small amount of Pd/C cat. were added to methanol (200 ml) and the mixture was hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen ceased. Following filtration through celite, the methanol was evaporated under reduced pressure to give the title compound, 7.0 g (92%).

¹H-NMR (300 MHz, CDCl₃): δ 3.3 (s, 2H), 3.9 (s, 3H), 4.75 (s, 2H), 7.45 (s, 1H), 8.35 (s, 1H)

15

Example 2.3

Synthesis of methyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate

20

Methyl 5,6-diaminonicotinate (0.9 g, 5.4 mmol) and 3-bromo-2-butanone (0.9 g, 6.0 mmol) were added to acetonitrile (30 ml) and refluxed for 24 h. Upon cooling some of the product was filtered off as hydrobromide salt. 20 ml of the filtrate was evaporated under reduced pressure and diethyl ether was added. More product was filtrated off as hydrobromide salt. The salt was dissolved in methylene chloride and washed with a bicarbonate solution. The organic layer was separated, dried over Na₂SO₄ and evaporated under reduced pressure to give 0.7 g (59%) of the desired compound.

25

¹H-NMR (300 MHz, CDCl₃): δ 2.4 (s, 6H), 3.9 (s, 3H), 4.5 (s, 2H), 6.85 (s, 1H), 8.1 (s, 1H)

30

*Example 2.4**Synthesis of methyl 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate*

Methyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (0.7 g, 3.2 mmol), 2-ethyl-6-methylbenzylchloride (0.54 g, 3.2 mmol), potassium carbonate (0.9 g, 6.4 mmol) and a cat. amount of potassium iodide were added to acetonitrile (20 ml) and were refluxed for 6 h. Following filtration, the acetonitrile was evaporated under reduced pressure to give an oil. The oily residue was solved in methylene chloride and washed with water. The organic layer was separated, dried over Na₂SO₄ and evaporated under reduced pressure to give a solid. Purification by column chromatography on silica gel using methylene chloride : ethylacetate (10 : 1) as eluent gave 0.42 g (38%) of the title compound.

¹H-NMR (500 MHz, CDCl₃): δ 1.15 (t, 3H), 2.35 (s, 3H), 2.4 (s, 3H), 2.43 (s, 3H), 2.75 (q, 2H), 4.0 (s, 3H), 4.25 (d, 2H), 4.9 (bs, 1H), 6.8 (s, 1H), 7.05-7.2 (m, 3H), 8.1 (s, 1H)

*Example 2.5**Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid*

Methyl 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate (0.4 g, 1.1 mmol) was added to a mixture of 1,4-dioxane (6 ml) and 2 M NaOH (6 ml) and was refluxed for 30 min. The dioxane was evaporated under reduced pressure and the aqueous solution was made acidic by addition of 2 M HCl. The acidic aqueous was basified by the addition of a saturated bicarbonate solution and the solid that formed was isolated by filtration to give 0.35 g (91%) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ 1.15 (t, 3H), 2.2 (s, 3H), 2.35 (s, 6H), 2.7 (q, 2H), 4.35 (d, 2H), 4.65 (t, 1H), 6.8 (s, 1H), 7.05-7.2 (m, 3H), 7.95 (s, 1H)

Example 2.6

Synthesis of ethyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate

Ethyl 5,6-diaminonicotinate (1.4 g, 7.7 mmol) and 3-bromo-2-butanon (1.16 g, 7.2 mmol) were added to 1,2-dimethoxyethan (50 ml) and refluxed for 20 h. The solvent was evaporated under reduced pressure and the residue was dissolved in methylene chloride. The methylene chloride solution was washed with saturated sodium bicarbonate and dried (Na₂SO₄). The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using methylene chloride : methanol (10 : 1) as eluent to give 0.3 g (17 %) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.4 (t, 3H), 2.4 (s, 6H), 4.35 (q, 2H), 4.6 (s, 2H), 6.75 (s, 1H), 8.2 (s, 1H)

Example 2.7

Synthesis of ethyl 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate

Ethyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (0.7 g, 3.0 mmol), 2-ethyl-6-methylbenzylchloride (0.5 g, 3.0 mmol), sodium carbonate (0.64 g, 6.0 mmol) and a cat. amount of potassium iodide were added to acetone (50 ml) and were refluxed for 20 h. Following filtration, the acetone was evaporated under reduced pressure to give an oil. The oily product was purified by column chromatography on silica gel using diethyl ether : petroleum ether (1:1) as eluent to give 0.12 g (9%) of the title product.

¹H-NMR (500 MHz, CDCl₃): δ 1.25 (t, 3H), 1.5 (t, 3H), 2.35 (s, 3H), 2.42 (s, 3H), 2.44 (s, 3H), 2.75 (q, 2H), 4.45-4.5 (m, 4H), 4.9 (bs, 1H), 6.8 (s, 1H), 7.05-7.2 (m, 3H), 8.1 (s, 1H)

Example 2.8

5

Synthesis of 6-amino-5-nitronicotinamide

A solution of 6-chloro-5-nitronicotinoyl chloride (38 g, 0.2 mol) in tetrahydrofuran (500 ml) was stirred at +5°C and ammonia was bubbled into the solution. After 1 h the reaction mixture was allowed to warm to room temperature and ammonia was bubbled into the solution for additional 2.5 h. The reaction mixture was stirred at room temperature for 20 h. The solids were removed by filtration, washed thoroughly with water and were dried under reduced pressure to give 18.5 g (51%) of the title compound.

15 ¹H-NMR (400 MHz, DMSO-d₆): δ 7.4 (s, 1H), 8.05 (s, 1H), 8.3 (s, 2H), 8.8 (s, 2H)

Example 2.9

Synthesis of 5,6-diaminonicotinamide

20

A suspension of 6-amino-5-nitronicotinamide (18 g, 99 mmol) and a cat. amount of Pd/C in methanol (600 ml) and the mixture was hydrogenated at room temperature and atmospheric pressure until the uptake of hydrogen ceased. Following filtration through celite, the methanol was evaporated under reduced pressure to give the title compound, 14.5 g (96%).

25

¹H-NMR (300 MHz, DMSO-d₆): δ 5.0 (bs, 2H), 6.1 (bs, 2H), 6.9 (bs, 1H), 7.15 (s, 1H), 7.55 (bs, 1H), 7.9 (s, 1H)

30 Example 2.10

Synthesis of 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide

5,6-Diaminonicotinamide (12.5 g, 82 mmol), 3-bromo-2-butanon (13.6, 90 mmol) and acetonitrile (150 ml) were refluxed for 20 h. Additional 3-bromo-2-butanon (4.0 g, 26.5 mmol) was added and the reaction mixture was refluxed for 5 h. Upon cooling the solids were removed by filtration. The solids were added to methylene chloride (150 ml), methanol (150 ml) and potassium carbonate (22 g, 160 mmol) and were stirred for 30 min. The solids were removed by filtration and evaporation of the solvents under reduced pressure gave an oily residue. Purification by column chromatography on silica gel eluting with methylene chloride : methanol (5:1) gave 3.3 g (20%) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ 2.25 (s, 3H), 2.35 (s, 3H), 5.6 (s, 2H), 6.65 (s, 1H), 7.15 (bs, 1H), 7.85 (bs, 1H), 8.05 (s, 1H)

Example 2.11

Synthesis of ethyl 8-amino-6-(aminocarbonyl)-2-methylimidazo[1,2-a]pyridine-3-carboxylate

5,6-Diaminonicotinamide (2.0 g, 13.4 mmol), ethyl-2-chloroacetoacetate (2.38 g, 14.4 mmol) and ethanol (40 ml) were refluxed for 20 h. The precipitate was isolated by filtration and washed with ethanol and diethyl ether. The solids were suspended in water, basified with a sodium hydroxide solution and isolated by filtration. Washing the solids with water and diethyl ether gave 0.42 g (12%) of the desired product.

¹H-NMR (500 MHz, DMSO-d₆): δ 1.4 (t, 3H), 2.6 (s, 3H), 4.35 (q, 2H), 5.95 (bs, 2H), 6.9 (s, 1H), 7.35 (bs, 1H), 8.0 (bs, 1H), 9.0 (s, 1H)

Example 2.12

Synthesis of ethyl 6-(aminocarbonyl)-8-(2-ethyl-6-methylbenzylamino)-2-methylimidazo[1,2-a]pyridine-3-carboxylate

Ethyl 8-amino-6-(aminocarbonyl)-2-methylimidazo[1,2-a]pyridine-3-carboxylate (0.41 g, 1.6 mmol), 2-ethyl-6-methylbenzylchloride, sodium carbonate (0.7 g, 6.6 mmol), sodium iodide (0.15 g, 1.0 mmol) and acetone (20 ml) were refluxed for 44 h. Methylene chloride was added and the solids were removed by filtration. The filtrate was evaporated under reduced pressure and purification of the residue by column chromatography on silica gel eluting with methylene chloride : methanol (100 : 4) gave 0.35 g (56%) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.25 (t, 3H), 1.45 (t, 3H), 2.35 (s, 3H), 3.65 (s, 3H), 2.7 (q, 2H), 4.4-4.45 (m, 4H), 5.0 (t, 1H), 6.95 (s, 1H), 7.0-7.2 (m, 3H), 9.2 (s, 1H)

Example 2.13

Synthesis of 8-amino-2-methylimidazo[1,2-a]pyridine-6-carboxamide mesylate

5,6-diaminonicotinamide (10 g, 66 mmol), chloroacetone (6.1 g, 66 mmol) and sodium bicarbonate (11.2 g, 132 mmol) were added to dimethylformamide (200 ml) and the mixture was stirred for 72 h. at room temperature. Most of the solvent was evaporated under reduced pressure and methanesulfonic acid (6 g, 63 mmol) was added. More solvent was evaporated under reduced pressure and ethanol was added to the residue. Upon warming the mixture to 60 °C. the product crysstallized as salt and was filtered off to give 6 g (32 %) of the title compound.

¹H-NMR (400 MHz, CDCl₃): δ 2.3 (s, 6H), 7.25 (s, 1H), 7.4 (s, 1H), 7.6 (s, 1H), 7.75 (s, 1H), 7.85 (s, 1H), 7.9 (s, 1H), 8.15 (s, 1H), 8.6 (s, 1H)

Example 2.14

Synthesis of 1-bromo-2-isopropyl-6-methylbenzene

2-isopropyl-6-methylanilin (14.9 g, 0.1 mol) was solved in conc hydrobromic acid (40 ml) and the mixture was cooled to 5 °C. Sodium nitrite (7.0 g, 0.1 mol) in water (15 ml) was added so that the temperature was below 10 °C. A solution of copper(I)bromide in conc
5 hydrobromic acid (10 ml) was added to the reaction mixture and the temperature was allowed to raise to room temperature. The mixture was stirred for 1h. at room temperature and 30 min at 40 °C Hexane was added and the organic layer was separated and evaporated under reduced pressure. Purification by column chromatography on silica gel using hexane as eluent gave 6.9 g (32 %) of the title compound as an oil.

10 ¹H-NMR (300 MHz,CDCl₃): δ 1.23 (d, 6H), 2.43 (s, 3H), 3.4-3.55 (m, 1H), 7.05-7.2 (m, 3H)

Example 2.15

15

Synthesis of 2-isopropyl-6-methylbenzaldehyd

To a solution of 1-bromo-2-isopropyl-6-methylbenzene (6.9 g, 32.4 mmol) in diethyl ether (50 ml) was added magnesium turnings (0.9 g, 37 mmol) and the mixture was refluxed in
20 nitrogen atmosphere until the reaction was started and was then stirred overnight at room temperature. Dimethylformamide (4 ml) was added dropwise during 10 min. and the mixture was stirred for 30 min. Saturated ammoniumchloride solution (30 ml) was added and the mixture was stirred for 1h. The organic layer was separated, filtrated and evaporated under reduced pressure. Purification by column chromatography on silica gel
25 using hexane:methylene chloride (3:2) as eluent gave 1.75 g (33 %) of the title compound .

¹H-NMR (500 MHz,CDCl₃): δ 1.25 (d, 6H), 2.55 (s, 3H), 3.7-3.8 (m, 1H), 7.1-7.4 (m, 3H), 10.65 (s, 1H)

30 Example 2.16

Synthesis of 2-isopropyl-6-methylbenzylalcohol

To a solution of 2-isopropyl-6-methylbenzaldehyd (1.75 g, 10.8 mmol) in methanol (15 ml) was added sodium borohydride (0.35 g, 9.5 mmol) and the mixture was stirred 1 h. at room temperature. The solvent was evaporated under reduced pressure and to the residue was added hexane and water. The organic layer was separated and evaporated under reduced pressure to give 1.73 g (98 %) of the title compound as an oil.

$^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 1.25 (d, 6H), 2.45 (s, 3H), 3.3-3.4 (m, 1H), 4.8 (s, 2H), 7.05- 7.2 (m, 3H)

10 *Example 2.17*

Synthesis of 2-isopropyl-6-methylbenzylchloride

To a solution of 2-isopropyl-6-methylbenzylalcohol (1.7 g, 10.4 mmol) in methylene chloride (20 ml) was added thionyl chloride (1.7 g, 14 mmol) and the reaction was stirred for 1 h. at room temperature. The solvent was evaporated under reduced pressure and the residue was filtrated through silica gel using methylenechloride as eluent. The solvent was evaporated under reduced pressure to give 1.83 g (96 %) of the title compound as an oil.

20 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 1.25 (d, 6H), 2.45 (s, 3H), 3.25-3.35 (m, 1H), 4.75 (s, 2H), 7.05-7.25 (m, 3H)

Example 2.18

25 *Synthesis of 2-bromo-6-methylbenzylbromide*

A mixture of 3-bromo-o-xylene (15 g, 81 mmol), N-bromo succinimid (15.1 g, 85.1 mmol), dibenzoylperoxid (0.65 g) and tetrachloromethane (150 ml) was refluxed for 5 hours. After filtration the filtrate was washed with sodium hydrogensulfite and water. The organic layer was dried over sodium sulfate and evaporated *in vacuo*. Chromatography (SiO₂) (petroleum ether: ethyl acetate, 100:4) gave a 16.8 g fraction of a mixture containing 45 % of the title compound. This mixture was used without further purification.

¹H-NMR (300 MHz, CDCl₃): δ 2.5 (s, 3H), 4.65 (s, 2H), 7.05-7.45 (m, 3H)

Example 2.19

5 *Synthesis of 2-(2-bromo-3-methylphenyl)acetonitril*

2-bromo-1-(bromomethyl)-3-methylbenzene (15 g, 0.057 mmol) and potassium cyanide (9.6 g, 0.148 mol) were added to dimethylformamide (75 ml) and stirred at 90 °C overnight. The solvent was evaporated under reduced pressure and the residue partitioned
10 between water (150 ml) and methylene chloride. The aqueous layer was extracted twice with methylene chloride, the organic extracts was separated, washed twice with water and was evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using heptane:methylene chloride (3:7) as eluent gave 8.0 g (67 %) of the title compound.

15

¹H-NMR (500 MHz, CDCl₃): δ 2.44 (s, 3H), 3.86 (s, 2H), 7.22-7.37 (m, 3H)

Example 2.20

20 *Synthesis of 2-(2-bromo-3-methylphenyl)acetic acid*

2-(2-bromo-3-methylphenyl)acetonitril (8.0 g, 0.038 mol) was added to a mixture of water (60 ml) and sulfuric acid (50 ml) and the mixture was refluxed overnight. After cooling to room temperature water (200 ml) was added and the mixture was extracted twice with
25 methylene chloride. The methylene chloride extracts were combined, washed twice with water, dried and evaporated under reduced pressure to give 7.9 g (90.8 %) of the title compound.

30

¹H-NMR (400 MHz, CDCl₃): δ 2.42 (s, 3H), 3.86 (s, 2H), 7.09-7.18 (m, 3H)

Example 2.21

Synthesis of ethyl 2-(2-bromo-3-methylphenyl)acetate

2-(2-bromo-3-methylphenyl)acetic acid (7.9 g, 0.034 mol) and sulfuric acid (0.1 ml) were added to ethanol (25 ml) and the mixture was refluxed overnight. The solvent was evaporated and to the residue was added saturated sodium carbonate. The aqueous solution was extracted twice with diethyl ether, the organic extracts were combined, washed twice with water, dried and evaporated under reduced pressure to give the desired product as an oil. (8.5 g, 97.7%).

¹H-NMR (400 MHz, CDCl₃): δ 1.24 (t, 3H), 2.40 (s, 3H), 3.78 (s, 3H), 4.16 (q, 2H), 7.06-7.14 (m, 3H)

10

Example 2.22

Synthesis of 2-(2-bromo-3-methylphenyl)-1-ethanol

LiAlH₄ (3.1 g, 0.083 mol) was suspended in dry tetrahydrofuran (100 ml) in argon atmosphere. Ethyl 2-(2-bromo-3-methylphenyl)acetate (8.5 g, 0.033 mol) dissolved in dry tetrahydrofuran (50 ml) was added and the mixture was stirred at room temperature for 4 h. The mixture was cooled on ice and 3.1 ml of water was added dropwise, followed by 3.1 ml of 15% sodium hydroxide and then 9.3 ml of water. After 15 h. the solids were removed by filtration and washed thoroughly with tetrahydrofuran. The filtrate was removed under reduced pressure. Purification of the residue by filtrating through silica gel using methylene chloride : methanol (9:1) as eluent gave 7.0 g (98.6 %) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃): δ 2.39 (s, 3H), 3.00 (t, 2H), 3.81 (t, 2H), 7.04-7.10 (m, 3H)

25

Example 2.23

Synthesis of benzyl 2-bromo-3-methylphenethyl ether

30

Sodium hydride (50 % in oil) (1.7 g, 0.036 mol) was suspended in dry tetrahydrofuran (75 ml) in argon atmosphere. 2-(2-bromo-3-methylphenyl)-1-ethanol (7.0 g, 0.033 mol) dissolved in tetrahydrofuran (25 ml) was added dropwise during 30 min at room temperature. Benzyl bromide (6.2 g, 0.036 mol) was added and the reaction mixture was stirred at room temperature over night. Water (1.0 ml) was added carefully and the solvent was evaporated

35

under reduced pressure. The residue was partitioned between water and diethyl ether and the water layer was extracted twice with diethyl ether. The ether extracts were combined, washed twice with water, and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using heptane:methylene chloride (7:3) as eluent gave 7.5 g (74.3 %) of the title compound.

¹H-NMR (400 MHz, CDCl₃): δ 2.38 (s, 3H), 3.10 (t, 2H), 3.69 (t, 2H), 4.51 (s, 2H), 7.04-7.08 (m, 3H), 7.21-7.30 (m, 5H)

Example 2.24

Synthesis of 2-[2-(benzyloxy)ethyl]-6-methylbenzaldehyde

To a solution of benzyl 2-bromo-3-methylphenethyl ether (3.2 g, 0.0105 mol) in dry tetrahydrofuran in a nitrogen atmosphere at -65 °C was added tert-butyllithium (1.7 M in pentane) (10.5 ml, 0.018 mol) and the mixture was stirred at -20 °C for 30 min. Dimethylformamide (1.5 g, 0.021 mol) was added dropwise at -65 °C and the mixture was stirred at -20 °C for 30 min and at room temperature for 1 h. To the solution was water added carefully and 2M HCl to make it acidic and the mixture was stirred for 30 min. To the mixture was added diethyl ether (50 ml), the organic layer was separated, washed with saturated sodium carbonate and water. The organic layer was separated, dried and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using heptane:methylene chloride (2:8) as eluent gave 1.0 g (38.5 %) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 2.55 (s, 3H), 3.23 (t, 2H), 3.66 (t, 2H), 4.46 (s, 2H), 7.05-7.31 (m, 8H), 10.54 (s, 1H)

Example 2.25

Synthesis of 8-((2-[2-(benzyloxy)ethyl]-6-methylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide

To a solution of 8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide mesylate 1.4 g (0.0038 mol) in methanol (20 ml) in a nitrogen atmosphere was added zinc chloride (1.0

g, 0.0039 mol) solved in methanol(10 ml) and the mixture was stirred for 30 min. To the mixture were added 2-[2-(benzyloxy)ethyl]-6-methylbenzaldehyde (1.0 g, 0.0039 mol) and sodium cyano borohydride (0.48 g, 0.0076 mol) and the mixture was refluxed overnight. The reaction mixture was cooled to room temperature, triethylamine (4 ml) was added, the mixture was stirred for 30 min, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using methylene chloride:methanol (9:1) as eluent. The residue was solved in diethyl ether, treated with diethyl ether/HCl and the precipitated product as HCl salt was filtered off. The salt was solved in methylene chloride and washed with saturated sodium carbonate. The organic layer was separated, washed with water, dried and evaporated under reduced pressure to give 0.13 g (7.7 %) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 2.31 (s, 3H), 2.33 (s, 3H), 2.34 (s, 3H), 2.98 (t, 2H), 3.66 (t, 2H), 4.37 (d, 2H), 4.46 (s, 2H), 5.02 (bs, 1H), 6.29 (bs, 2H), 6.47 (s, 1H), 7.03-7.26 (m, 8H), 7.91 (s, 1H)

Example 2.26

Synthesis of 2-ethyl-6-methylbenzyl 5-(2-ethyl-6-methylbenzyloxy)-6-nitronicotinate

5-hydroxy-6-nitronicotinic acid (1 g, 5 mmol), 2-ethyl-6-methylbenzylchloride (1.85 g, 11 mmol), N,N-diisopropylamine (1.75 g, 14 mmol) and tetrabutylammonium iodide (0.1 g) was added to acetonitrile (10 ml) and was refluxed for 3 h. The solvent was evaporated under reduced pressure and the residue was solved in methylene chloride and washed with water. The organic layer was separated, dried and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel using n-hexane:methylene chloride (1:1) as eluent gave 0.7 g (29 %) of the title compound.

¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 3H), 1.25 (t, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 2.7 (q, 2H), 2.8 (q, 2H), 5.25 (s, 2H), 5.55 (s, 2H), 7.05-7.3 (m, 6H), 8.2 (s, 1H), 8.65 (s, 1H)

Example 2.27

Synthesis of 6-amino-5-(2-ethyl-6-methylbenzyloxy)nicotinamide

2-ethyl-6-methylbenzyl 5-(2-ethyl-6-methylbenzyloxy)-6-nitronicotinate (0.7 g, 2 mmol) was added to a solution of ammonia in methanol (5-10 %)(40 ml) and the mixture was stirred at 35 °C for 96 h. The solvent was evaporated under reduced pressure. Purification of the residue twice by column chromatography on silica gel using ethylacetate:methylene chloride (1:1) and methanol:methylene chloride (1:9) as eluent gave 0.14 g (31 %) of the title compound.

¹H-NMR (500 MHz, CDCl₃): δ 1.21 (t, 3H), 1.87 (s, 2H), 2.37 (s, 3H), 2.72 (q, 2H), 5.11 (s, 2H), 5.99 (bs, 2H), 7.1-7.3 (m, 3H), 7.67 (d, 1H), 8.09 (d, 1H)

BIOLOGICAL TESTS

1. *In vitro* experiments

15 *Acid secretion inhibition in isolated rabbit gastric glands*

Inhibiting effect on acid secretion *in vitro* in isolated rabbit gastric glands was measured as described by Berglindh et al. (1976) Acta Physiol. Scand. 97, 401-414.

20 *Determination of H⁺, K⁺-ATPase activity*

Membrane vesicles (2.5 to 5 µg) were incubated for 15 min at +37°C in 18 mM Pipes/Tris buffer pH 7.4 containing 2 mM MgCl₂, 10 mM KCl and 2 mM ATP. The ATPase activity was estimated as release of inorganic phosphate from ATP, as described by LeBel et al. (1978) Anal. Biochem. 85, 86-89.

2. *In vivo* experiments

Inhibiting effect on acid secretion in female rats

30

Female rats of the Sprague-Dawley strain are used. They are equipped with cannulated fistulae in the stomach (lumen) and the upper part of the duodenum, for collection of

gastric secretions and administration of test substances, respectively. A recovery period of 14 days after surgery is allowed before testing commenced.

Before secretory tests, the animals are deprived of food but not water for 20 h. The stomach
5 is repeatedly washed through the gastric cannula with tap water (+37°C), and 6 ml Ringer-
Glucose given subcutaneously. Acid secretion is stimulated with infusion during 2.5-4 h
(1.2 ml/h, subcutaneously) of pentagastrin and carbachol (20 and 110 nmol/kg·h,
respectively), during which time gastric secretions are collected in 30-min fractions. Test
substances or vehicle are given either at 60 min after starting the stimulation (intravenous
10 and intraduodenal dosing, 1 ml/kg), or 2 h before starting the stimulation (oral dosing, 5
ml/kg, gastric cannula closed). The time interval between dosing and stimulation may be
increased in order to study the duration of action. Gastric juice samples are titrated to pH
7.0 with NaOH, 0.1 M, and acid output calculated as the product of titrant volume and
concentration.

15

Further calculations are based on group mean responses from 4-6 rats. In the case of
administration during stimulation; the acid output during the periods after administration of
test substance or vehicle are expressed as fractional responses, setting the acid output in the
30-min period preceding administration to 1.0. Percentage inhibition is calculated from the
20 fractional responses elicited by test compound and vehicle. In the case of administration
before stimulation; percentage inhibition is calculated directly from acid output recorded
after test compound and vehicle.

Bioavailability in rat

25

Adult rats of the Sprague-Dawley strain are used. One to three days prior to the
experiments all rats are prepared by cannulation of the left carotid artery under anaesthesia.
The rats used for intravenous experiments are also cannulated in the jugular vein (Popovic
(1960) J. Appl. Physiol. 15, 727-728). The cannulas are exteriorized at the nape of the
30 neck.

Blood samples (0.1 - 0.4 g) are drawn repeatedly from the carotid artery at intervals up to 5.5 hours after given dose. The samples are frozen until analysis of the test compound.

Bioavailability is assessed by calculating the quotient between the area under blood/plasma concentration (AUC) curve following (i) intraduodenal (i.d.) or oral (p.o.) administration
5 and (ii) intravenous (i.v.) administration from the rat or the dog, respectively.

The area under the blood concentration vs. time curve, AUC, is determined by the log/linear trapezoidal rule and extrapolated to infinity by dividing the last determined blood
10 concentration by the elimination rate constant in the terminal phase. The systemic bioavailability (F%) following intraduodenal or oral administration is calculated as
$$F(\%) = (AUC \text{ (p.o. or i.d.)} / AUC \text{ (i.v.)}) \times 100.$$

Inhibition of gastric acid secretion and bioavailability in the conscious dog.

15

Labrador retriever or Harrier dogs of either sex are used. They are equipped with a duodenal fistula for the administration of test compounds or vehicle and a cannulated gastric fistula or a Heidenhaim-pouch for the collection of gastric secretion.

20 Before secretory tests the animals are fasted for about 18 h but water is freely allowed. Gastric acid secretion is stimulated for up to 6.5 h infusion of histamine dihydrochloride (12 ml/h) at a dose producing about 80% of the individual maximal secretory response, and gastric juice collected in consecutive 30-min fractions. Test substance or vehicle is given orally, i.d. or i.v., 1 or 1.5 h after starting the histamine infusion, in a volume of 0.5 ml/kg
25 body weight. In the case of oral administration, it should be pointed out that the test compound is administered to the acid secreting main stomach of the Heidenham-pouch dog.


The acidity of the gastric juice samples are determined by titration to pH 7.0, and the acid
30 output calculated. The acid output in the collection periods after administration of test substance or vehicle are expressed as fractional responses, setting the acid output in the

fraction preceding administration to 1.0. Percentage inhibition is calculated from fractional responses elicited by test compound and vehicle.

Blood samples for the analysis of test compound concentration in plasma are taken at
5 intervals up to 4 h after dosing. Plasma is separated and frozen within 30 min after
collection and later analyzed. The systemic bioavailability (F%) after oral or i.d.
administration is calculated as described above in the rat model.

CLAIMS

1. A compound of the formula I



I

or a pharmaceutically acceptable salt thereof, wherein

R¹ is

- (a) H,
- (b) CH₃, or
- (c) CH₂OH;

R² is

- (a) CH₃
- (b) CH₂CH₃

R³ is (a) H

- (b) C₁-C₆ alkyl,
- (c) hydroxylated C₁-C₆ alkyl
- (d) halogen

R⁴ is

- (a) H,
- (b) C₁-C₆ alkyl,

(c) hydroxylated C₁-C₆ alkyl, or

(d) halogen;

R⁵ is

5 (a) H, or

(b) halogen;

R⁶, R⁷ are the same or different

10 (a) H,

(b) C₁-C₆ alkyl;

(c) hydroxylated C₁-C₆ alkyl

(d) C₁-C₆ alkoxy-substituted C₁-C₆ alkyl

15

X is

(a) NH, or

(b) O.

20 2. A compound according to claim 1 wherein R¹ is CH₃ or CH₂OH; R², R³ and R⁴ independently are CH₃ or CH₂CH₃; and R⁵ is H, Br, Cl, or F.

3. The compound according to claim 1 or 2 being

25 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-propyl-imidazo[1,2-a]pyridine-6-carboxamide,

8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide,

30 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide,

8-(2-ethyl-6-methylbenzylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-dimethylbenzyl-amino)-imidazo[1,2-a]pyridine-6-carboxamide,

N-[2-(dimethylamine)-2-oxoethyl]-8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide

2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate,

2,3-dimethyl-8-(2-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate,

2,3-dimethyl-8-(2-methyl-6-isopropylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate,

2,3-dimethyl-8-(2,6-diethyl-benzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-ethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3 dimethyl-8-(2-ethyl-6-methyl-benzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide,

N-(2,3-dihydroxypropyl)-2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-[1,2-a]pyridine-6-carboxamide,

2,3 dimethyl-8-(2-ethyl-6-methyl-benzylamino)-N-(2-methoxyethyl)-imidazo[1,2-a]pyridine-6-carboxamide,

2-methyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-bromo-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-(2-hydroxyethyl)-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

8-(2-ethyl-6-methylbenzylamino)-N,N-bis(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide,

8-(2-ethyl-6-methylbenzylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-ethyl-6-methylbenzyloxy)-imidazo[1,2-a]pyridine-6-carboxamide,
or

a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 or 2 being;

8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethyl-2-methylimidazo[1,2-a]pyridine-
5 6-carboxamide,

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-
6-carboxamide,

2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-
carboxamide,

10 8-(2-ethyl-6-methylbenzylamino)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-
carboxamide,

2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3-dimethyl-8-(2-ethyl-4-fluoro-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-
carboxamide,

15 2,3-dimethyl-8-(2,6-dimethyl-4-fluoro-benzylamino)-imidazo[1,2-a]pyridine-6-
carboxamide,

2,3-dimethyl-8-(2,6-diethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide,

2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-hydroxyethyl-imidazo[1,2-
a]pyridine-6-carboxamide,

20 2,3 dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-(2-methoxyethyl)-imidazo[1,2-
a]pyridine-6-carboxamide,

or


a pharmaceutically acceptable salt thereof.

25 5. A compound according to any of claims 1-4 as a hydrochloride or mesylate salt.

6. Products containing at least one compound according to any of claims 1-4 and at least
one antimicrobial agent as a combined preparation for simultaneous, separate or
sequential use in the prevention or treatment of gastrointestinal inflammatory diseases.


7. Products containing at least one compound according to any of claims 1-4 and at least one proton pump inhibitor as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of gastrointestinal inflammatory diseases.
8. A process for the preparation of a compound according to any one of claims 1 to 5, wherein X is NH, comprising

(a) reacting a compound of the Formula II




II

with a compound of the Formula III



III


wherein R⁶ and R⁷ are as defined in claim 1, in an inert solvent, to a compound of the Formula IV,



IV


61

(b) reacting a compound of the Formula IV wherein R^6 and R^7 are as defined in claim 1, with ammonia in an inert solvent to a compound of the Formula V




5

(c) reducing a compound of the Formula V wherein R^6 and R^7 are as defined in claim 1 in an inert solvent under standard conditions to a compound of the Formula VI




10

(d) reacting a compound of the Formula VI wherein R^6 and R^7 are as defined in claim 1 with a compound of Formula VII




15

wherein R^2 is as defined in claim 1, Z is a leaving group and R^9 represent H, CH_3 or an ester group, in an inert solvent with or without a base to a compound of the Formula VIII




VIII

(e) reacting a compound of the Formula VIII wherein R^6 , R^7 and R^2 are as defined in claim 1, and R^9 is H, CH_3 or an ester group with a compound of Formula IX



IX

wherein R^3 , R^4 , and R^5 are as defined in claim 1, and Y is a leaving group in an inert solvent with or without a base, to a compound of the Formula X




X

(f) reducing a compound of Formula X wherein R^9 is an ester group in an inert solvent to a compound of the Formula I wherein R^1 is CH_2OH and X is NH.


9. A process for the preparation of a compound according to any one of claims 1 to 5, wherein X is NH and R¹ is H or CH₃, comprising

- 5 (a) reacting a compound of the Formula II



II


- 10 with an alcohol compound of the general formula R¹⁰-OH, wherein R¹⁰ is an alkyl group under standard conditions, to a compound of the Formula XI



XI


- 15 (b) reacting a compound of the Formula XI wherein R¹⁰ is an alkyl group, with ammonia in an inert solvent under standard conditions to a compound of the Formula XII

64




XII

(c) reducing a compound of the Formula XII wherein R^{10} is an alkyl group in an inert solvent under standard conditions to a compound of the Formula XIII




XIII

(d) reacting a compound of the Formula XIII wherein R^{10} is an alkyl group with a compound of Formula XIV




XIV

wherein R^2 is as defined in claim 1, Z is a leaving group and R^{11} represent H or CH_3 , in an inert solvent with or without a base to a compound of the Formula XV




XV

(e) reacting a compound of the Formula XV wherein R^{10} is an alkyl group, R^2 are as defined in claim 1 and R^{11} is H or CH_3 with a compound of Formula IX




IX

wherein R^3 , R^4 , and R^5 are as defined in claim 1 and Y is a leaving group in an inert solvent with or without a base to a compound of the Formula XVI



XVI

(f) reacting a compound of Formula XVI wherein R^2 , R^3 , R^4 and R^5 are as defined in claim 1, R^{10} is an alkyl group and R^{11} is H or CH_3 with a compound of Formula III




III

wherein R^6 and R^7 are as defined in claim 1, under standard conditions, to a compound of Formula I wherein R^1 is H or CH_3 and X is NH.


10. A process for the preparation of a compound according to any one of claims 1 to 5 comprising

(a) treating a compound of Formula XVII




XVII

wherein R^1 , R^2 , R^3 , R^4 , R^5 and X are as defined in claim 1 and R^{10} is an alkyl group, with acid or base under standard conditions to a compound of Formula XVIII



XVIII

(b) reacting a compound of Formula XVIII wherein R^1 , R^2 , R^3 , R^4 , R^5 and X is defined in claim 1 with a compound of Formula III



5

wherein R^6 and R^7 are as defined in claim 1, in the presence of a coupling reagent in an inert solvent under standard conditions, to a compound of Formula I.

10

11. A compound according to any one of claims 1 to 5 for use in therapy.

12. A pharmaceutical formulation containing a compound according to any one of claims 1 to 5 as active ingredient in combination with a pharmaceutically acceptable diluent or carrier.

15

13. Use of a compound according to any one of claims 1 to 5 for the manufacture of a medicament for the inhibition of gastric acid secretion.

14. Use of a compound according to any one of claims 1 to 5 for the manufacture of a medicament for the treatment of gastrointestinal inflammatory diseases.


20

15. Use of a compound according to any one of claims 1 to 5 the manufacture of a medicament for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, wherein the said salt is adapted to be administered in combination with at least one antimicrobial agent.

25

16. A method for inhibiting gastric acid secretion which comprises administering to a mammal, including man, in need of such inhibition an effective amount of a compound according to any one of claims 1 to 5.


17. A method for the treatment of gastrointestinal inflammatory diseases which comprises administering to a mammal, including man, in need of such treatment an effective amount of a compound according to any one of claims 1 to 5.
18. A method for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, which comprises administering to a mammal, including humans, in need of such treatment an effective amount of a compound as claimed in any one of claims 1 to 5, wherein the said salt is administered in combination with at least one antimicrobial agent.
19. A pharmaceutical formulation for use in the inhibition of gastric acid secretion wherein the active ingredient is a compound according to any one of claims 1 to 5.
20. A pharmaceutical formulation for use in the treatment of gastrointestinal inflammatory diseases wherein the active ingredient is a compound according to any one of claims 1 to 5.
21. A pharmaceutical formulation for use in the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, wherein the active ingredient is a compound according to any one of claims 1 to 5 in combination for simultaneous, separate or sequential use or together with at least one antimicrobial agent.
22. A compound of the formula VIII



VIII

wherein R^2 , R^6 and R^7 are as defined in claim 1, and R^9 is H, CH_3 or an ester group.


23. A compound of the formula X



X

wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 are as defined in claim 1, and R^9 is an ester group.


24. A compound of the formula XV



XV

wherein R^2 is as defined in claim 1, R^{10} is an alkyl group and R^{11} is H or CH_3 .


25. A compound of the formula XVI



XVI

5 wherein R^2 , R^3 , R^4 and R^5 are as defined in claim 1, R^{10} is an alkyl group and R^{11} is H or CH_3 .

26. A compound of the formula



XVIII

10 wherein R^1 , R^2 , R^3 , R^4 , R^5 and X are as defined in claim 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/00663

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C07D 471/04, A61K 31/435 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0308917 A2 (FUJISAWA PHARMACEUTICAL, CO., LTD.), 29 March 1989 (29.03.89) --	1-15,19-23
A	J. Med. Chem., Volume 28, 1985, James J. Kaminski et al, "Antiulcer Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidazo(1,2-a)pyridines" page 876 - page 892 --	1-15,19-23
A	EP 0033094 A1 (SCHERING CORPORATION), 5 August 1981 (05.08.81) --	1-15,19-23
A	EP 0228006 A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 8 July 1987 (08.07.87) --	1-15,19-23
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
9 Sept 1999		10 -09- 1999
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Göran Karlsson/Els Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/00663

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0204285 A1 (FUJISAWA PHARMACEUTICAL CO., LTD.), 10 December 1986 (10.12.86) -- -----	1-15,19-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/00663

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16-18
because they relate to subject matter not required to be searched by this Authority, namely:
**A method for treatment of the human or animal body by therapy,
see rule 39.1**
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-15, 19-23

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE99/00663

The subjects, defined by the problems and their means of solution, as listed below are so different from each other that no technical relationship or interaction can be appreciated to be present so as to form a single general inventive concept. The acceptance of a single general inventive concept covering the end products as well as products used to prepare these and products (intermediates) implies that when several claimed intermediates are implied in different reactions, these intermediates are technically closely inter-connected with the end products as well as with themselves by their use for incorporation of the same essential structural part into the end products.

1. claims 1-15, 19-21 and claims 22 and 23, intermediates VIII and X
2. claim 24, intermediate XV
3. claims 25 and 26, intermediates XVI and XVIII

The special technical feature of invention 1 is compound I containing an amide group in position 6 and intermediates VIII and X, which are specially designed for the preparation of compound I. Compounds I, VIII and X do not contain a common technical feature together with intermediates XV, XVI or XVIII. Therefore, a single inventive concept based on the relationship intermediates/end products is lacking.

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/08/99

International application No.

PCT/SE 99/00663

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0308917 A2	29/03/89	AU 2278388 A CN 1033628 A DK 532088 A FI 884318 A JP 1151579 A US 4920129 A	06/04/89 05/07/89 25/03/89 25/03/89 14/06/89 24/04/90
EP 0033094 A1	05/08/81	SE 0033094 T3 AU 540840 B AU 6633781 A CA 1167845 A DK 25081 A FI 810147 A GR 72960 A HK 94187 A IE 50682 B JP 56113782 A MY 76087 A NZ 196071 A OA 6727 A PT 72370 A,B ZA 8100219 A	06/12/84 30/07/81 22/05/84 24/07/81 24/07/81 19/01/84 18/12/87 11/06/86 07/09/81 31/12/87 31/05/84 30/06/82 01/02/81 27/01/82
EP 0228006 A1	08/07/87	AT 71625 T AU 593802 B AU 5834586 A CA 1257264 A DE 3683403 A DK 250386 A EP 0204285 A,B FI 862210 A GR 861379 A JP 62187471 A US 4725601 A US 4782055 A	15/02/92 22/02/90 11/12/86 11/07/89 27/02/92 05/12/86 10/12/86 05/12/86 28/08/86 15/08/87 16/02/88 01/11/88
EP 0204285 A1	10/12/86	AT 71625 T AU 593802 B AU 5834586 A CA 1257264 A DE 3683403 A DK 250386 A FI 862210 A GR 861379 A JP 62016483 A US 4725601 A EP 0228006 A JP 62187471 A US 4782055 A	15/02/92 22/02/90 11/12/86 11/07/89 27/02/92 05/12/86 05/12/86 28/08/86 24/01/87 16/02/88 08/07/87 15/08/87 01/11/88